Hepatitis B and C

被引：26

作者：

Karnsakul, Wikrom ^{[1
]}

Schwarz, Kathleen B. ^{[2
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Pediat, Pediat Liver Ctr, 600 North Wolfe St,CMSC 2-117, Baltimore, MD 21287 USA

[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Pediat Liver Ctr, 600 North Wolfe St,CMSC 2-116, Baltimore, MD 21287 USA

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2017年 / 64卷 / 03期

关键词：

Hepatitis B; Hepatitis C; Sustained virologic response; Pegylated interferon; Direct-acting antiviral agents; Spontaneous viral clearance; ALPHA-2B PLUS RIBAVIRIN; TO-CHILD TRANSMISSION; GENOTYPE; INFECTION; BREAST-FED INFANTS; VIRUS-INFECTION; PEGYLATED INTERFERON; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; RISK-FACTORS; FOLLOW-UP;

D O I：

10.1016/j.pcl.2017.01.007

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.

引用

页码：641 / +

页数：20

共 50 条

[1] Cost-effectiveness of viral hepatitis B & C treatment
Toy, Mehlika
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2013, 27 (06) : 973 - 985
[2] Hepatitis B and C
Duddempudi, Anupama T.
Bernstein, David E.
CLINICS IN GERIATRIC MEDICINE, 2014, 30 (01) : 149 - +
[3] Genotype Distributions and Hepatitis B Coinfection in Hepatitis C Patients at a University Hospital
Aydin, Ozlem
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2021, 27 (01): : 13 - 18
[4] Hepatitis B and C in Children
Sperry, A. Bailey
Bennett, Aaron
Wen, Jessica
CLINICS IN LIVER DISEASE, 2022, 26 (03) : 403 - 420
[5] Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C
Cortez, Karoll J.
Kottilil, Shyam
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (01) : 4 - 14
[6] Hepatitis B and C
Mysore, Krupa R.
Leung, Daniel H.
CLINICS IN LIVER DISEASE, 2018, 22 (04) : 703 - +
[7] Seroprevalence of hepatitis B and hepatitis C markers in adolescents in Southern Brazil
Scaraveli, Natalia Gazzoni
Passos, Ana Maria
Voigt, Andreia Royer
do Livramento, Andrea
Tonial, Gabriela
Treitinger, Aricio
Spada, Celso
CADERNOS DE SAUDE PUBLICA, 2011, 27 (04): : 753 - 758
[8] Interaction Between Hepatitis B, Hepatitis C and Alcohol in the Development of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Poorolajal, Jalal
Shadi, Yahya
Heshmati, Bahram
JOURNAL OF VIRAL HEPATITIS, 2025, 32 (01)
[9] Hepatitis B and C in Pregnancy and Children: A Canadian Perspective
Mendlowitz, Andrew B.
Feld, Jordan J.
Biondi, Mia J.
VIRUSES-BASEL, 2023, 15 (01):
[10] Performance and Validation of Chronic Liver Disease Questionnaire-Hepatitis C Version (CLDQ-HCV) in Clinical Trials of Patients with Chronic Hepatitis C
Younossi, Zobair M.
Stepanova, Maria
Henry, Linda
VALUE IN HEALTH, 2016, 19 (05) : 544 - 551

← 1 2 3 4 5 →